Parathyroid Adenoma with Fibrous Dysplasia of Maxilla and Mandible in a Patient with End Stage Renal Disease (ESRD) on Routine Hemodialysis: A Case Report
Abstract
Introduction: End Stage Renal Disease (ESRD) can cause secondary hyperparathyroidism, resulting in parathyroid hyperplasia. In parathyroid hyperplasia, monoclonal development can occur, resulting in nodular hyperplasia. This nodular hyperplasia was thought to develop into a carcinoma, but its development into a benign neoplasm is very rare. This case report presents a parathyroid adenoma that developed in a patient with endstage renal failure who required routine hemodialysis.
Case Presentation: A 31yearold woman presented with complaints of facial bone swelling, shortened body, and a previous history of renal failure with hemodialysis therapy since 4 years ago. From the blood test, a hyperparathyroid condition was found, and a history of hypocalcemia. A sestamibi (MIBI) examination has also been done with the results of bilateral inferior parathyroid adenomas. The patient was diagnosed with bilateral inferior parathyroid adenoma with endstage renal disease (ESRD) on hemodialysis and bilateral inferior parathyroidectomy was performed on the patient. The patient’s progress was followed from diagnosis, surgery, and followup after surgery. At 4 months postoperatively, the suspicion of a mass in the residual parathyroid was confirmed by parathyroid hormone (PTH) and MIBI examination. The patient was suspected to have parathyroid hyperplasia in the remaining gland, with risk factors for hyperparathyroidism due to ESRD.
Conclusions: ESRDinduced secondary hyperparathyroidism may lead to enlargement of all parathyroid glands which may develop into nodules. Therefore, careful monitoring and diagnostics supported by hospital policy is required and removal of all parathyroid glands is considered in such patients, even if not all parathyroid glands have masses.
Keywords
DOI: 10.33371/ijoc.v18i4.1249
Article Metrics
Abstract View: 360, 
PDF Download: 288
References
Wieneke JA, Smith A. Parathyroid adenoma. Head and neck pathology. 2008;2:305-8.
Devita VTL, Theodore S.; Rosenberg, Steven A. Cancer: Principles and Practice of Oncology. 12th Edition ed: Wolters Kluwer; 2023.
Al-Salameh A, Cadiot G, Calender A, Goudet P, Chanson P. Clinical aspects of multiple endocrine neoplasia type 1. Nature Reviews Endocrinology. 2021;17(4):207-24.
Imanishi Y, Tahara H, Palanisamy N, Spitalny S, Salusky IB, Goodman W, et al. Clonal chromosomal defects in the molecular pathogenesis of refractory hyperparathyroidism of uremia. Journal of the American Society of Nephrology. 2002;13(6):1490-8.
Drüeke TB. Hyperparathyroidism in chronic kidney disease. Endotext [Internet]. 2021.
Goto S, Komaba H, Fukagawa M. Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention. NDT plus. 2008;1(suppl_3):iii2-iii8.
Mendes V, Jorgetti V, Nemeth J, Lavergne A, Lecharpentier Y, Dubost C, et al. Secondary hyperparathyroidism in chronic haemodialysis patients: a clinico-pathological study. Proceedings of the European Dialysis and Transplant Association European Dialysis and Transplant Association. 1983;20:731-8.
Yuen NK, Ananthakrishnan S, Campbell MJ. Hyperparathyroidism of renal disease. Permanente Journal. 2016;20(3).
Saliba W, El-Haddad B. Secondary hyperparathyroidism: pathophysiology and treatment. The Journal of the American Board of Family Medicine. 2009;22(5):574-81.
Moghadam RN, Amlelshahbaz AP, Namiranian N, Sobhan-Ardekani M, Emami-Meybodi M, Dehghan A, et al. Comparative diagnostic performance of ultrasonography and 99mTc-sestamibi scintigraphy for parathyroid adenoma in primary hyperparathyroidism; systematic review and meta-analysis. Asian Pacific journal of cancer prevention: APJCP. 2017;18(12):3195.
Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GEH, Marcocci C, Minisola S, et al. Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop. Journal of Bone and Mineral Research. 2020;37(11):2293-314.
El‐Hajj Fuleihan G, Chakhtoura M, Cipriani C, Eastell R, Karonova T, Liu JM, et al. Classical and nonclassical manifestations of primary hyperparathyroidism. Journal of Bone and Mineral Research. 2020;37(11):2330-50.
Agrawal K, Arya AK, Sood A, Kumari P, Singh P, Sapara M, et al. A detailed appraisal of renal manifestations in primary hyperparathyroidism from Indian PHPT registry: Before and after curative parathyroidectomy. Clinical Endocrinology. 2021;94(3):371-6.
Kochman M. Primary hyperparathyroidism: clinical manifestations, diagnosis and evaluation according to the Fifth International Workshop guidelines. Reumatologia. 2023;61(4):256-63.
Anitha A, Babu K, Siddini V, Ballal H. Primary hyperparathyroidism in a child. Indian Journal of Nephrology. 2015;25(3):171-3.
Pradhan R, Agarwal A, Gupta SK. PHPT masquerading as rickets in children and presenting with rare skeletal manifestations: report of three cases and review of literature. Indian Journal of Endocrinology and Metabolism. 2018;22(5):705-9.
Habas E, Sr., Eledrisi M, Khan F, Elzouki AY. Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management. Cureus. 2021;13(7):e16388.
Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Journal of the American Society of Nephrology. 2004;15(8):2208-18.
Martin KJ, González EA. Metabolic bone disease in chronic kidney disease. Journal of the American Society of Nephrology. 2007;18(3):875-85.
Chudek J, Ritz E, Kovacs G. Genetic abnormalities in parathyroid nodules of uremic patients. Clinical cancer research: an official journal of the American Association for Cancer Research. 1998;4(1):211-4.
Tominaga Y, Tsuzuki T, Uchida K, Haba T, Otsuka S, Ichimori T, et al. Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney international. 1999;55(4):1375-83.
Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1, 25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. The Journal of Clinical Investigation. 1993;92(3):1436-43.
Brown AJ, Ritter CS, Finch JL, Slatopolsky EA. Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate. Kidney international. 1999;55(4):1284-92.
DRU TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. Journal of the American Society of Nephrology. 2000;11(6):1141-52.
Moran CAK, Neda; Weissferdt, Annika. Oncological Surgical Pathology: Springer Nature Switzerland; 2020.
Buicko JL, Kichler KM, Amundson JR, Scurci S, Kozol R. The sestamibi paradox: improving intraoperative localization of parathyroid adenomas. The American Surgeon. 2017;83(8):832-5.
McBiles M, Lambert AT, Cote MG, Kim SY, editors. Sestamibi parathyroid imaging. Seminars in nuclear medicine; 1995: Elsevier.
Holzheimer RG, Mannick JA. Surgical treatment: evidence-based and problem-oriented. 2001.
Krol JP, Joosten FBM, de Boer H, Bernsen MLE, Slump CH, Oyen WJG. Four-dimensional computed tomography as first-line imaging in primary hyperparathyroidism, a retrospective comparison to conventional imaging in a predominantly single adenoma population. EJNMMI Reports. 2024;8(1):11.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Email this article 
